Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating the pharmacokinetics and safety of XEMBIFY versus Gamunex-C in participants with CIDP; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Gamunex-C (intravenous immunoglobulin (IVIG))
• XEMBIFY (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Status: RECRUITING